The expression of insulin-like growth factor-I (IGF-I) was measured at the mRNA and protein level in myometrium and fibroids from women with and without preoperative treatment with a gonadotrophinreleasing hormone (GnRH) agonist for 3 months, from post-menopausal women, from pregnant women and in myometrium from women without fibroid disease. Women with menstrual periods were classified according to the phase of the cycle. In tissues from non-treated premenopausal women, IGF-I mRNA expression was significantly higher in fibroids than in myometrium, with no differences related to phase of the menstrual cycle. In post-menopausal women and in GnRH agonist-treated women responding to treatment, similar mRNA expression was seen in myometrium and fibroids but the concentrations were lower than in untreated premenopausal women. The IGF-I mRNA value in fibroids from pregnant women was higher than in any other group and myometrium from pregnant women exhibited higher mRNA expression than myometrium from non-treated premenopausal women. The IGF-I protein was more abundant in fibroids than in myometrium of non-treated premenopausal and of pregnant women and in both tissues the concentration was significantly higher in the group of pregnant women. The IGF-I protein concentrations in fibroids and myometrium from GnRH agonist-treated and post-menopausal women were similar to those from premenopausal non-treated women. High sex steroid concentrations in pregnant and non-pregnant women of fertile age seem to be associated with a higher expression of IGF-I in fibroids than in myometrium, suggesting that IGF-I contributes to the selective growth advantage of these tumours.
Introduction
When trying to explain the selective growth advantage of fibroids, several investigations have focused the interest on Uterine fibroids, or leiomyomata, are the most common factors that are differentially expressed in fibroids and surtumours in the female genital tract. They are benign and rounding myometrium (for review, see Andersen and Barbieri, although many never give rise to symptoms, these tumours 1995). Although some of these investigations support the may cause bleeding disturbances, pelvic discomfort or pain and, concept that both hormone receptors and growth factors might occasionally, recurrent abortion and infertility. The circulating be important for the differences in growth regulation, so far concentrations of oestrogen and progesterone are considered no consistent hypothesis for this interaction has been presented. to be the major determinant for fibroid growth as these tumours
The insulin-like growth factors (IGFs) constitute a family of stop growing and decrease in size after menopause. The size polypeptides with insulin-like and growth promoting activities of fibroids (and of the myometrium) can be reduced by down- (Humbel, 1990) . They are produced not only in the liver but regulation of ovarian oestrogen and progesterone secretion with also in several extrahepatic tissues, including the uterus. Several gonadotrophin-releasing hormone (GnRH) agonists (Friedman studies indicate that both IGF-I and IGF-II are expressed and et al., 1987) . The average decrease in volume of the fibroids secreted in both fibroids and adjacent myometrium (Rein et al. , following this treatment has been reported as Ͼ50% whereas 1990; Giudice et al., 1993; Vollenhoven et al., 1993) . In the the effect on total uterine volume is less pronounced (Puzigaca rat uterus, the expression of IGF-I (but not of IGF-II) has been et al ., 1994) . Antiprogestins have been shown to decrease the shown to be regulated by oestrogens (Norstedt et al., 1989) . size of fibroids to a similar degree (Murphy et al., 1993) .
In humans, the hormonal influence on expression is less clear, During pregnancy, fibroids often increase in size during the although a down-regulation of both IGF-I and IGF-II by GnRH first two trimesters, whereas very few continue to grow during agonists has been suggested (Rein et al., 1990) . Previous the last trimester and most fibroids even shrink (Lev-Toaff studies indicate that membrane preparations from fibroids have et al., 1987) . The reason for this lack of growth response, more high affinity binding sites for IGF-I than myometrium, despite high serum concentrations of sex steroids during late pregnancy, is unknown. whereas no such difference could be seen for the binding of mRNA values were determined by hybridization of TNA in solution as IGF-II (Tommola et al., 1989; Chandrasekhar et al., 1992) .
previously described (Durnam and Palmiter, 1983 (Ghahary and Murphy, 1989; Jones and Clemmons, 1995 
Assay of IGF-I and sex steroids
were collected from 18 untreated premenopausal women, from 13 premenopausal women treated with a GnRH analogue (Goserelin;
Total IGF-I concentrations in tissue and in serum were determined Zoladex ® ; Astra-Zeneca, UK) for 2-3 months before surgery, from by radioimmunoassay with a commercial kit from Nichols Products five post-menopausal women and from five pregnant women. Of the Corporation (San Juan Capistrano, CA, USA). Tissue specimens latter group, one underwent hysterectomy at 12 weeks gestation since (100-200 mg) were cut from the frozen biopsies with a prechilled large fibroids made a regular abortion impossible, whereas the other scalpel, weighed and cut into smaller pieces. The minced tissue was four were subject to Caesarean section at term. From pregnant women transferred to a prechilled (dry ice) capsule containing a tungsten only two paired samples of myometrium and fibroid(s) were collected.
ball. The capsule was frozen in liquid nitrogen and thereafter shaken Myometrium only was collected from seven premenopausal and five at 1600 oscillations/min for 30 s in a dismembranation apparatus post-menopausal women operated for other gynaecological diseases, (Retsch, GmbH, Haan, Germany). This procedure was repeated once not involving uterine enlargement and at Caesarean section from after intermediate freezing in liquid nitrogen. The pulverized tissue seven pregnant women without fibroids. In all, 66 different fibroids was then transferred to a prechilled tube and suspended in 10 volumes and 36 myometrial samples from 41 women with fibroid disease were of buffer containing 10 mmol/l Tris, 1.5 mmol/l EDTA and 5.0 mmol/ analysed with respect to IGF-I mRNA expression, whereas the l Na 2 MoO 4, (sodium molybdate) adjusted to pH 7.4 with HCl. The corresponding analysis of the IGF-I protein was performed on 26 suspension was centrifuged at 24000 g for 30 min at ϩ4°C and the fibroids and 22 myometria from 26 women. The number of fibroids supernatant was transferred to a prechilled tube and frozen at -70°C. per woman did not differ between groups.
IGF-I was extracted from tissue homogenate and from serum with Menstrual cycle pattern and last menstrual period (LMP) were acid ethanol, as suggested by the manufacturer of the radioimmunonoted for all women of fertile age and information about the response assay kit. The concentrations are expressed in µg of the World Health to treatment in terms of amenorrhoea or decreased bleeding was Organization (WHO) First International Reference Reagent IGF-I 87/ collected in GnRH agonist-treated women. All post-menopausal 518 (WHO, 1988) . The detection limit in serum using the standard women except one had reached menopause Ͼ6 years ago and their procedure suggested by the manufacturer was 0.6 µg/l and the interpost-menopausal status was confirmed by high FSH concentrations.
and intra-assay coefficients of variation were 6 and 10% respectively. Ultrasound measurements were performed in GnRH agonist-treated Serial dilutions of extracts from fibroid and myometrial tissue yielded women before treatment and a few days before surgery. Fibroids and dilution curves parallel to the standard curve. Total protein in the myometrial tissue were collected immediately at hysterectomy or at tissue homogenates was determined by the Biuret method (Lowry enucleation of fibroids. Tissue for mRNA and IGF-I analysis was et al., 1951) . immediately frozen in liquid nitrogen and stored at -70°C. Serum Serum concentrations of oestradiol 17β, progesterone and FSH samples were collected between 07:00 and 08:00 on the morning of were determined by enhanced luminiscence competititve immunosurgery and stored at -20°C. assay using commercial kits (Amerlite ® ; Amersham International, Little Chalfont, Bucks, UK). Serum FSH concentrations are expressed Histopathological analysis as IU/l of the Second WHO FSH IRP 78/549. Detection limits and within and between assay coefficients were 13.3 and 14.8% for 50 Tissue for routine histopathological examination was collected, fixed pmol/l oestradiol; 11.1 and 16.9% for 0.35 nmol/l progesterone; and in buffered formaldehyde solution and embedded in paraffin. Sections 5.0 and 7.6% for 0.5 IU/l FSH respectively. In the statistical were stained with haematoxylin and eosin and histopathological calculations values below the detection limits were set to 25 pmol/l examination was performed to classify the lesions and to study the for oestradiol and to 0.20 nmol/l for progesterone respectively. endometrium with respect to the phase of the menstrual cycle.
Statistical analysis mRNA analysis
Total nucleic acids (TNA) were prepared according to Durnam A mean number of 1.8 fibroids per woman with fibroid disease was analysed. The mean value of 1-6 fibroids was calculated for each and Palmiter (1983) and TNA concentrations were determined by spectrophotometry. The DNA content was measured by fluorimetry patient and used for further statistical analysis. The Kruskal-Wallis test was used to clarify whether differences between groups were (Labarca and Pagen, 1980) to certify the RNA/DNA-ratio. IGF-I 
Results
Data concering parity and serum concentrations of oestradiol and progesterone and FSH are given in Table I . Non-treated responders', depending on clinical response in terms of (n ϭ 4) (n ϭ 6) decreased fibroid volume and on oestradiol concentrations. Nine of these women responded to treatment with serum a Significantly different from the corresponding myometrium (Wilcoxon signed rank test; P Ͻ 0.05).
oestradiol concentrations of Ͻ100 pmol/l and a measurable decrease in fibroid size, while four did not respond, either in terms of decreased oestradiol concentration or in terms of were significantly higher in fibroids than in myometrium. This difference was not present in GnRH agonist-treated and postreduced fibroid volume. The GnRH agonist-treated patients had a lower parity than the other premenopausal patients and, menopausal patients. GnRH agonist-treated patients not responding to treatment had higher IGF-I mRNA values in in seven out of 13 patients, a myomectomy and not a hysterectomy was performed, because of a desire for premyometrium and in fibroids than the corresponding group of patients responding to treatment and the difference was served fertility.
No cycle phase-related differences in IGF-I were observed significant in the myometrium. No further statistical comparisons were made for the group of non-responders. No tissue in untreated premenopausal women with fibroids, either at the mRNA level or in protein concentrations (Tables II and III). difference was observed in pregnant women, but the IGF-I mRNA value in fibroids was significantly higher than in In the statistical analysis, we therefore considered the untreated 'cycling' patients of fertile age as one single group. Five fibroids from untreated premenopausal women. Myometrium from pregnant women with or without fibroids had higher control patients without fibroids were in the proliferative phase and two were in the secretory phase of the cycle and these mRNA expression than the corresponding groups of nontreated premenopausal women, but this difference was women were also considered as one group in comparison with the other categories.
significant only in myometrium from controls without fibroids. The mRNA level in fibroids and myometrium from both IGF-I mRNA values are shown in Table II and Figure 1 . The IGF-I mRNA values in non-treated premenopausal women
GnRH agonist responders and post-menopausal patients was releasing hormone (GnRH)-agonist treated and pregnant women untreated premenopausal, post-menopausal, gonadotrophin-releasing with fibroids. All GnRH agonist-treated patients responded to hormone (GnRH) agonist-treated premenopausal and pregnant treatment. Individual observations are indicated for each group and women. The GnRH agonist patients were subdivided as responders the solid lines represent medians. α Significantly different from the (resp) or non-responders (non-resp) dependent on whether or not corresponding myometrium (Wilcoxon signed rank test for the they responded to treatment. Control myometrium (C) was premenopausal group); P Ͻ 0.05 and the standardized t-test for the collected from premenopausal, post-menopausal and pregnant pregnant group; P Ͻ 0.05). β Significantly different from patients without uterine disease. Individual observations are myometrium from untreated premenopausal women (Mannindicated for each group and the solid lines represent medians.
Whitney U-test; P Ͻ 0.05). γ Significantly different from fibroids α Significantly different from the corresponding myometrium from untreated premenopausal women (Mann-Whitney U-test; (Wilcoxon signed rank test; P Ͻ 0.05). To compare myometrium P Ͻ 0.05). and fibroids in post-menopausal and pregnant women, the standardized t-test was used. oestradiol concentration and IGF-I mRNA expression in the myometrium in all groups (r s ϭ 0.66, P ϭ 0.0006, n ϭ 28), significantly lower than that from non-treated premenopausal except the pregnant women (where oestradiol concentrations women. mRNA expression in the myometrium was significwere in another range) and a significant correlation was also antly lower in post-menopausal than in premenopausal observed in the fibroids (r s ϭ 0.61, P ϭ 0.002, n ϭ 27). No control patients.
significant correlation was observed between serum oestradiol Tissue concentrations of IGF-I in myometrium and fibroids concentrations and tissue IGF-I protein, either in fibroids or from patients are given in Figure 2 . Due to lack of sufficient in myometrium. material tissue IGF-I was measured only in a limited number of samples. The concentrations of IGF-I were higher in fibroids Discussion than in myometrium from non-treated premenopausal and in pregnant patients, whereas no such difference was seen in the The present study demonstrates that uterine fibroids have higher IGF-I mRNA expression and higher tissue concentration GnRH agonist-treated or post-menopausal women. The IGF-I concentration in both fibroids and myometrium from pregnant of IGF-I protein than the corresponding myometrium in nontreated women of fertile age. Previous reports concerning women was significantly higher than in the corresponding tissues from the untreated premenopausal group. No significant tissue differences in IGF-I mRNA expression have been inconsistent, showing higher expression in fibroids than in difference in IGF-I was observed in fibroids or in myometrium from GnRH agonist-treated or post-menopausal patients, when myometrium (Hoppener et al., 1988; Boehm et al., 1990) or no difference between the tissues (Vollenhoven et al., 1993) . compared with the corresponding tissues from untreated premenopausal patients. No correlations were found between These discrepancies might partly be due to the fact that fibroids are individual tumours where the expression of IGF-I varies tissue and serum IGF-I concentrations (data not shown).
A significant positive correlation between IGF-I mRNA and considerably between fibroids from the same patient, which is also the case for another endocrine related variable, i.e. sex The authors also presented data favouring the view that IGF-I is required for G 2 progression in the oestradiol-induced steroid receptor contents (Englund et al., 1998) . In the present study, up to a four-fold difference in mRNA expression was mitotic cycle. These findings further support the concept that IGF-I has a key role in uterine growth control. observed between fibroids from the same patient. This implies the importance to analyse more than one fibroid from each
The down-regulation of IGF-I mRNA in post-menopausal and GnRH agonist-treated women is not reflected at the protein patient whenever possible.
The influence of ovarian sex steroids on IGF-I mRNA level. This discrepancy might suggest a post-transcriptional modification of IGF-I gene expression or indicate that the expression in fibroids and in myometrium is clearly demonstrated by the lower expression observed in both fibroids and endocrine mechanisms involved in regulation of receptors and/ or IGFBPs differ from those that determine IGF-I tissue myometrium from post-menopausal and GnRH agonist-treated women responding to treatment and the significant correlation concentrations. However, it is important to keep in mind that the total tissue content of IGF-I determined by the method between serum oestradiol and IGF-I mRNA values. It is also worth noting that protein differences were not present under used here by no means reflect the biological availability of the protein, as both bound and unbound IGF-I are measured. these conditions, i.e. oestrogen-depletion. However, in these two groups the tissue concentrations of IGF-I remained high,
The high IGF-I and IGF-I mRNA values observed in both fibroids and myometrium of term pregnant women is in although the lack of tissue difference was similar to the mRNA data. In contrast, no variation due to phase of the menstrual accordance with previous observations (Stjernholm et al., 1996) where a four-fold higher amount of IGF-I mRNA was cycle was observed, either for IGF mRNA expression or for IGF-I protein. It has been suggested that the IGF-I mRNA found in the cervix of term pregnant, compared with nonpregnant, women. It is presently difficult to say whether expression in fibroids is influenced by oestrogen and enhanced during the late proliferative phase of the menstrual cycle the observed increase in IGF-I expression is related to the stimulatory effect of high sex steroid levels during pregnancy . This is supported by our findings of significant correlations between serum oestradiol and IGF-I or whether the high levels of placental growth hormone, especially during the second half of pregnancy, contributes mRNA levels in both myometrium and fibroids. The lack of menstrual cycle related variation suggests that a more detailed (Caufries et al., 1993) . However, the alterations may also be part of more specific responses of the uterus, in terms of, e.g. subclassification, with a larger patient material, may be necessary to further analyse this issue.
remodelling of connective tissue before parturition. Taken together, the present study favours the view that IGFAnother study (Vollenhoven et al., 1994) reported no differences in mRNA expression of IGF-I, IGF-II or the IGF binding I is involved in sex steroid-mediated growth regulation of both fibroids and myometrium in the human uterus. However, to proteins (IGFBPs), either in fibroids or in myometrium, from women pretreated with a GnRH agonist, compared with tissues be able to measure and evaluate the bioavailability and effects of the protein, further information about the receptors and from untreated women. Our data indicate that reduction of both fibroids and mean uterine volume in GnRH agonistbinding proteins and their endocrine regulation is essential. treated and post-menopausal women is associated not only with decreased concentrations of oestradiol and progesterone
